Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 4/20 | 0.35 |
| ▸ | FPR3 | P25089 | 6/20 | 0.35 |
| ▸ | FPR2 | P25090 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3367087 | 1.00 | DGAT1 (0.38) | DGAT1CPB2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3367092 | 1.00 | DGAT1 (0.38) | DGAT1CPB2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3368795 | 0.86 | CPB2 (0.39) | DGAT1CPB2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3368783 | 0.86 | CPB2 (0.39) | DGAT1CPB2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4464180 | 0.86 | CPB2 (0.39) | DGAT1CPB2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3368786 | 0.86 | CPB2 (0.39) | DGAT1CPB2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4464185 | 0.86 | CPB2 (0.39) | DGAT1CPB2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3369093 | 0.83 | USP30 (0.41) | DGAT1CPB2BCL2FPR3FPR2 | |
| SCHEMBL3369097 | 0.83 | USP30 (0.41) | DGAT1CPB2BCL2FPR3FPR2 | |
| SCHEMBL3369092 | 0.83 | USP30 (0.41) | DGAT1CPB2BCL2FPR3FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646629-B1 | CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK SHARP & DOHME (US) | 2010-06-23 | — | — | EP | disclosed |
| US-7582659-B2 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7462633-B2 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070203187-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK & CO., INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20050038092-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | MERCK SHARP & DOHME CORP. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203187-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | OXA1L, ALAD, COASY | DGAT1 2869/4885CPB2 1912/4885NPC1 1541/4885 |
| US-20050038092-A1 | Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof | OXA1L, ALAD, COASY | DGAT1 2869/4885CPB2 1912/4885NPC1 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.